Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

from Reuters: Health News https://ift.tt/2Nt6swI